Laurus Labs Limited
₹2,392.00+₹147.00 (+6.5%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹57,182 Cr
- P/E
- 83.8x
- EV / EBITDA
- 73.3x
- Revenue
- ₹5,217 Cr
- Net margin
- 4.7%
- ROCE
- 11.9%
Price chart
Technical chartScreen technicals →+146.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +20.7%
- 3M
- +34.3%
- 6M
- +117.6%
- 1Y
- +146.6%
- 5Y
- +379.7%
52-week range
Day change +₹147.00 (+6.5%) from ₹2,245 to ₹2,392 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in LAURUSLABS, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Large-cap with ₹57.2K Cr market capitalisation
Concerns1
- Low return on equity of 5.3%
Rule-based from financial data. Not advice.
About the company
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas.
Read moreShow less
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
- Sector
- Healthcare
- Shares outstanding
- 54.0 Cr shares
- ISIN
- INE947Q01028
- BSE code
- 540222
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹57,182 Cr
- P/E
- 83.8x
- P/B
- 11.6x
- EV / EBITDA
- 73.3x
- EV / Sales
- 12.2x
- P/S
- 11.9x
- Earnings yield
- 1.2%
- 52-week high
- ₹2,392.00
- 52-week low
- ₹920.70
Profitability
- Operating margin
- 15.6%
- Net margin
- 4.7%
- EBITDA margin
- 16.6%
- ROE
- 5.3%
- ROCE
- 11.9%
- ROA
- 2.9%
- Dividend payout
- 19.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 15.6%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹5,217 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.4%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 11.5%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹798 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -46.7%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 69.6%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -3.5%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹659 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -25.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹8.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.2%
Solvency and efficiency
- Current ratio
- 3.31
- Debt / Equity
- 0.50
- Debt / Assets
- 0.28
- Debt / EBITDA
- 2.64
- Interest coverage
- 4.97
- Financial leverage
- 1.82
- CFO / Net profit
- 2.94
- Cash / Market cap
- 6.7%
- Cash per share
- ₹71.07
- Asset turnover
- 0.63
- Fixed asset turnover
- 1.58
- Capital intensity
- 0.63
- Debtor days
- 124 days
- Inventory turnover
- 1.41
- Cash conversion cycle
- 231 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹7 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹4,273 Cr |
| Sales | Operating profit | ₹944 Cr |
| Operating profit | Interest | ₹182 Cr |
| Operating profit | Depreciation | ₹359 Cr |
| Operating profit | Profit before tax | ₹403 Cr |
| Other income | Profit before tax | ₹100 Cr |
| Profit before tax | Tax and other | ₹124 Cr |
| Profit before tax | Net profit | ₹380 Cr |
Revenue and net profit
Revenue grew 8.4% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹4,769 Cr | ₹956 Cr |
| FY2022 | ₹4,707 Cr | ₹750 Cr |
| FY2023 | ₹5,773 Cr | ₹760 Cr |
| FY2024 | ₹4,812 Cr | ₹224 Cr |
| FY2025 | ₹5,217 Cr | ₹380 Cr |
Cash flows
FY2025: ₹540 Cr from operations, -₹52.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹694 Cr | -₹206 Cr |
| FY2022 | ₹823 Cr | -₹14 Cr |
| FY2023 | ₹882 Cr | ₹147 Cr |
| FY2024 | ₹659 Cr | -₹98 Cr |
| FY2025 | ₹540 Cr | -₹52 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹5,217 Cr+8.4%1Y
- Net profit
- ₹380 Cr+69.6%1Y
- Cash from operations
- ₹540 Cr
- Free cash flow
- -₹52 Cr
- Revenue CAGR, 5Y
- 11.5%
- EBITDA CAGR, 5Y
- 6.7%
- Net profit CAGR, 5Y
- -3.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹5,217 Cr | ₹944 Cr | — | ₹380 Cr | ₹540 Cr | -₹52 Cr | 8.3% | +8.4% | +69.6% |
Monthly returns
Month-by-month returns of LAURUSLABS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹8,587 Cr |
| Equity capital | ₹108 Cr |
| Reserves | ₹4,456 Cr |
| Borrowings | ₹2,380 Cr |
| Other liabilities | ₹1,643 Cr |
| Assets | ₹8,587 Cr |
| Fixed assets | ₹2,888 Cr |
| Capital work in progress | ₹336 Cr |
| Investments | ₹740 Cr |
| Other assets | ₹4,623 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
LAURUSLABS trades at 83.8x earnings against a peer median of 52.6x (a 59% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Laurus Labs LimitedLAURUSLABSthis companyP/E ↑ premium | ₹57,182 Cr | 83.8x | 11.6x | 5.3% | 73.3x |
| Alkem Laboratories LimitedALKEM | ₹70,090 Cr | 31.4x | 5.1x | 16.6% | 33.0x |
| Fortis Healthcare LtdFORTIS | ₹68,497 Cr | 370.0x | 7.4x | 2.2% | 160.8x |
| Aurobindo Pharma Ltd.AUROPHARMA | ₹67,835 Cr | 33.6x | 3.2x | 9.9% | 23.8x |
| Abbott India Ltd.ABBOTINDIA | ₹59,620 Cr | 39.5x | 14.9x | 32.5% | 34.5x |
| Biocon Ltd.BIOCON | ₹56,868 Cr | 709.0x | 3.1x | 1.1% | 124.1x |
| Glenmark Pharmaceuticals ltdGLENMARK | ₹56,650 Cr | 38.5x | 2.4x | 22.5% | 7.3x |
| Procter & Gamble Hygiene & Health Care Ltd.PGHH | ₹40,121 Cr | 48.5x | 43.1x | — | — |
| GlaxoSmithkline Pharmaceuticals Ltd.GLAXO | ₹40,108 Cr | 42.4x | 23.5x | — | — |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
LAURUSLABS since 1 January, against earlier years.
Historical volatility
LAURUSLABS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 32.0% |
| FY2022 | 27.0% |
| FY2023 | 26.0% |
| FY2024 | 16.0% |
| FY2025 | 18.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹5,217 Cr |
| Costs | |
| Interest | ₹182 Cr |
| Expenses | ₹4,273 Cr |
| Operating profitOperating Profit | ₹944 Cr |
| Other income and charges | |
| Profit before tax | ₹504 Cr |
| Tax | |
| Net profitNet Profit | ₹380 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹8,587 Cr |
| Equity capitalEquity Capital | ₹108 Cr |
| Reserves | ₹4,456 Cr |
| Borrowings | ₹2,380 Cr |
| Other liabilitiesOther Liabilities | ₹1,643 Cr |
| AssetsTotal Assets | ₹8,587 Cr |
| Fixed assetsFixed Assets | ₹2,888 Cr |
| Capital work in progressCWIP | ₹336 Cr |
| Investments | ₹740 Cr |
| Other assetsOther Assets | ₹4,623 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹540 Cr |
| Investing cash flowCash from Investing Activity | -₹592 Cr |
| Financing cash flowCash from Financing Activity | ₹59 Cr |
| Change in cashNet Cash Flow | ₹8 Cr |
Learn while you research
Academy chapters picked for Laurus Labs Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 83.8, learn when high multiples are justified.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read